Role of Recombinants in Peach Allergy
Classification of Different Forms of Peach Allergy and the Role of Recombinant Allergens in the Diagnosis
1 other identifier
observational
148
1 country
1
Brief Summary
This study is aimed at verifying the role and the efficacy of the recombinants allergens Pru p 1, Pru p 3 and Pru p 4, Bet v 1, Bet v 2 and Bet v 4 in the diagnosis of peach allergy
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jul 2008
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2008
CompletedFirst Submitted
Initial submission to the registry
July 14, 2008
CompletedFirst Posted
Study publicly available on registry
July 15, 2008
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2009
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2010
CompletedFebruary 22, 2012
February 1, 2012
1.3 years
July 14, 2008
February 20, 2012
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Evaluation of diagnostic efficacy of PHADIA IMMUNO-CAP with the peach recombinant allergens Pru p 3, 1 and 4 as compared to peach IMMUNO-CAP in the identification of peach allergic subjects at major risk of anaphylaxis
1 year
Secondary Outcomes (1)
Evaluate whether the above recombinants allergens could help identifying subjects with severe reaction to other fruits
1 year
Study Arms (2)
A
Subjects with mild (S1) reaction to peach fruit
B
Subjects with severe reaction to peach fruit
Eligibility Criteria
Peach allergic subjects at major risk of anaphylaxis
You may qualify if:
- female and male;
- pts with 18 e 80 years old;
- signature of the informed consent form;
- CAP/RAST positive for peach;
- clinical manifestation of peach allergy
You may not qualify if:
- pregnancy;
- current antihistamine therapy;
- subjects that do not give consent to the study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Niguarda Hospital
Milan, Italy, 20162, Italy
Related Publications (2)
Pastorello EA, Farioli L, Pravettoni V, Scibilia J, Mascheri A, Borgonovo L, Piantanida M, Primavesi L, Stafylaraki C, Pasqualetti S, Schroeder J, Nichelatti M, Marocchi A. Pru p 3-sensitised Italian peach-allergic patients are less likely to develop severe symptoms when also presenting IgE antibodies to Pru p 1 and Pru p 4. Int Arch Allergy Immunol. 2011;156(4):362-72. doi: 10.1159/000324440. Epub 2011 Aug 9.
PMID: 21829031RESULTMascheri A, Farioli L, Pravettoni V, Piantanida M, Stafylaraki C, Scibilia J, Mirone C, Preziosi D, Nichelatti M, Pastorello EA. Hypersensitivity to Tomato (Lycopersicon esculentum) in Peach-Allergic Patients: rPrup 3 and rPrup 1 Are Predictive of Symptom Severity. J Investig Allergol Clin Immunol. 2015;25(3):183-9.
PMID: 26182684DERIVED
Biospecimen
Blood sample
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Elide A Patorello, MD
Niguarda Hospital
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 14, 2008
First Posted
July 15, 2008
Study Start
July 1, 2008
Primary Completion
October 1, 2009
Study Completion
November 1, 2010
Last Updated
February 22, 2012
Record last verified: 2012-02